Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection.
| Autor: | Mao, Xianhai, Duan, Xiaohui, Wu, Dongde, Zhou, Cuncai, Tian, Yifeng, Shen, Jian, Xu, Guohui, Lai, Jianlin |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p494-494, 151p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|